Technology Transfer Pact Could Be A Model for Future Agreements

Also See: Breadth of Biodiversity After months of complaints, hundreds of scientists will finally be able to use a long-coveted recombinant technology without looking over their shoulders. On August 19, National Institutes of Health Director Harold Varmus announced an agreement with DuPont Pharmaceuticals that will enable NIH and NIH-supported researchers to use a DuPont-developed technology, called Cre-lox, without compromising the company's ability to receive the appropriate value for commer

Written byEugene Russo
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Also See: Breadth of Biodiversity

In a separate agreement with DuPont, the Jackson Laboratory, a nonprofit institution in Bar Harbor, Maine, and a designated national repository for genetically engineered mice, will be permitted to receive, breed, and distribute animals containing Cre-lox to both academic and commercial institutions. All parties contend that the agreements could serve as models for future agreements between academic and commercial research institutions.

"What we've worked [out] with the NIH is a role model for how commercial institutions can put important inventions for free into the academic domain while retaining commercial rights that are reasonable," claims David Block, vice president of product planning and acquisition at DuPont.

Cre-lox allows investigators to efficiently cut out or put in any size chunk of DNA into a designated sector of the genome. It's the first technology that's been proven to do so in post-mitotic cells such as liver cells. "We're ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies